Molecular Imaging of Dementia With Lewy Bodies

2019 ◽  
pp. 59-93 ◽  
Author(s):  
Oliver Cousins ◽  
Tayyabah Yousaf ◽  
Heather Wilson ◽  
Gennaro Pagano ◽  
Marios Politis
Keyword(s):  
Molecular Imaging ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies

New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases

2018 ◽  
Vol 25 (26) ◽  
pp. 3105-3130 ◽  
Author(s):  
Matteo Bauckneht ◽  
Dario Arnaldi ◽  
Flavio Nobili ◽  
Dag Aarsland ◽  
Silvia Morbelli
Keyword(s):  
Molecular Imaging ◽  
Neurodegenerative Disorders ◽  
Lewy Body ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Accurate Diagnosis ◽  
Imaging Biomarkers ◽  
Number Of Individuals ◽  
New Evidence ◽  
Lewy Body Diseases

The term Lewy body diseases (LBDs) refers to a subset of neurodegenerative disorders that share the accumulation of the so-called Lewy bodies (LB) including: Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and PD later characterized by the occurrence of dementia (PDD). Moreover, multiple system atrophy (MSA) and idiopatic Rem Sleeping behaviour disorders (RBD) complete the group of synucleinopathies and have also common symptoms with respect to LBDs. The clinical diagnosis of LBDs can be challenging for physicians, particularly in the early stages of disease. Given the growing number of individuals affected by these neurodegenerative disorders, early and accurate diagnosis can lead to improved clinical management of patients. For this reason, information obtained from molecular imaging biomarkers is playing an increasingly important role in this framework. The present narrative review discusses both established milestones and new evidence on the use of molecular imaging tracers already part of the clinical practice as well as available evidence on new molecular imaging approaches in PD, PDD and DLB.

scholarly journals Multi-modality molecular imaging characteristics of dementia with Lewy bodies

2018 ◽  
Vol 46 (6) ◽  
pp. 2317-2326
Author(s):  
Zhong-Bao Gao ◽  
Wei Wang ◽  
Xing-Li Zhao ◽  
Tong Chen ◽  
Li-Ping Fu ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Amyloid Β ◽  
Amyloid Β Protein ◽  
Imaging Features ◽  
Imaging Characteristics ◽  
Positron Emission ◽  
Β Protein ◽  
Neurodegenerative Dementia

Objective Dementia with Lewy bodies (DLB) is a common type of neurodegenerative dementia. Molecular neuroimaging using dopamine transporter (DaT), Pittsburgh compound B (PIB), and fluorodeoxyglucose (FDG) positron emission tomography (PET) has advantages in detecting dopaminergic neuron loss, abnormal amyloid β-protein deposition, and glucose metabolism changes in patients with neurodegenerative disorders. However, the multi-modality molecular imaging features of patients with DLB have rarely been reported. Methods Five patients with a probable diagnosis of DLB were enrolled. PET/magnetic resonance imaging was performed with three tracers: 11C-β-CFT, 11C-PIB, and 18F-FDG. Clinical and imaging characteristics were analyzed. Results All patients with DLB showed reduced uptake in the bilateral putamen on DaT PET, increased uptake throughout the cerebral cortex on PIB PET, and intact metabolism of the posterior cingulate gyrus on FDG PET. Conclusion Multimodal molecular imaging is helpful for early diagnosis of DLB. Studies with larger sample sizes are needed to confirm the molecular imaging differences between DLB and Alzheimer’s disease and Parkinson’s disease dementia.

Differences in glucose metabolism between dementia with Lewy bodies and dementia associated with Parkinson's disease

2005 ◽  
Vol 32 (S 4) ◽  
Author(s):  
P Häussermann ◽  
A.O Ceballos-Baumann ◽  
H Förstl ◽  
R Feurer ◽  
B Conrad ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Glucose Metabolism ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies

Dementia with Lewy bodies

2018 ◽  
pp. 11-21
Author(s):  
O. S. Levin ◽  
E. E. Vasenina ◽  
A. Sh. Chimagomedova ◽  
N. G. Dudchenko
Keyword(s):  
Parkinson’S Disease ◽  
Dementia With Lewy Bodies ◽  
Cholinesterase Inhibitors ◽  
Lewy Bodies ◽  
Diagnosis And Treatment ◽  
Modern Concept ◽  
Historical Aspect ◽  
Neurodegenerative Process ◽  
Icd 10

Te lecture presents modern concept of the symptoms, diagnosis and treatment of dementia with Lewy bodies (DLB), which accounts for about 10% of cases of dementia. Te nosological status of DLB and the problem of ratio of DLB and Parkinson’s disease which, apparently, represent two phenotypic variants of one neurodegenerative process («diseases with Lewy bodies») are considered in historical aspect. Approaches to the diagnosis and coding of DLB in accordance with ICD-10 are proposed. Te role of cholinesterase inhibitors, antipsychotics, levodopa, rasagiline and other drugs in the treatment of patients with DLB is аnalyzed.

Sign in / Sign up

Export Citation Format

Share Document